Sessions

Workforce of the Future: Talent, Change Management and Enabling Future Development
Delivering Projects and Managing Timelines in the Variable, Continuously Changing Environment Of Cell and Gene Therapy
How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds
Patient and Payer Challenges: Enabling Access to Patients through Market Access, Pricing and Patient-Led Discussion
Moving the Industry Towards Automated Systems for Scale-up Success
Tech Review: New Platforms and Closed-Systems to Enable Commercial Success
Working With a CDMO is not Just an Outsourcing Contract but a Partnership: Learnings from Successful Biotech/CDMO Partnerships
Overcoming the Commercial Roadblocks for Cell and Gene Therapy Success
Overcoming the Commercial Roadblocks for Cell and Gene Therapy Success

Workforce of the Future: Talent, Change Management and Enabling Future Development

26 Jan 2022
13:30
SPONSORED BY
Heidrick & Struggles
Cell and Gene Therapy Catapult

13:30 Chairperson’s Opening
Jeff Boyd, Partner and Life Sciences Tools & Services Sector Co-Leader, Heidrick & Struggles

13:35 Presentation 1
Angela Justice, Chief People Officer, TCR2 Therapeutics

13:50 Presentation 2
Stephen Ward, Chief Manufacturing Officer, Cell & Gene Therapy Catapult

14:05 Building A Commercial Talent Engine for Cell & Gene 

  • Developing and commercializing innovative advanced therapies requires talent that is up for the task
  • Competencies and motivation required to develop and commercialize advanced therapies is distinct from traditional therapies
  • Keys to attracting and keeping talent in a highly competitive space
  • Lessons learned from small biotech and large pharma experiences

Jill Elliot, Vice President, Cell Therapy Commercialisation, Novo Nordisk

14:20 Presentation 4
Speaker TBD

14:35 Speaker Q&A and Panel Discussion

Speakers

Stephen Ward
Chief Manufacturing Officer
Cell and Gene Therapy Catapult
Jeff Boyd
Partner and Life Sciences Tools & Services Sector Co-Leader
Heidrick & Struggles
Jill Elliott
Vice President, Cell Therapy Commercialisation
Novo Nordisk